• From Bench to Bedside

    UMMS Licensing Revenue

    Ranked most recently at #14 in terms of licensing revenue in the U.S For FY 2015 ~ $32M and in 2006 -2015 ~ $395M

  • Three Graduate Schools

    The three UMMS graduate schools are the School of Medicine, the Graduate School of Biomedical Sciences and the Graduate School of Nursing with 1,300 faculty and only 1,100 graduate students.

    Read more
  • Research Awards

    FY 2014 ~ $244M & 3rd largest recipient of NIH funds among New England medical schools

    Read more
  • MassBiologics

    Fully-integrated developer of therapeutic biologics from discovery through GMP manufacturing.Only publicly-owned, FDA-licensed manufacturer of vaccines and other biologics in the U.S. Generated FY 2014 revenue of $41M

    Read more
  • Commonwealth Medicine

    UMMS’ healthcare consulting practice, generated FY 2014 revenue of $340M also Operates in 20 states and 27 countries.

    Read more

Welcome to the Office of Innovation & Business Development

Partnering Opportunities

The Office of Innovation and Business Development is responsible for developing and executing a comprehensive business strategy that promotes innovation, supports entrepreneurship, optimizes the institution’s research portfolio, and leverages the wide array of expertise and capabilities that exist throughout our academic community. 


  • 01/17/17

    "New battlegrounds in immunity revealed by evolution-guided studies"

    Hosted By: Beth McCormick, PhD - Microbiology and Physiological Systems (MaPS), UMMS
    Location: AS8-2072, Albert Sherman Center, UMMS
    12:00 pm - 1:00 pm

  • 01/17/17

    "Transcriptional regulation by tRNA fragments in the early embryo"(Rando), "Ribosomal proteins and RNA splicing machinery are the targets of Poly(GR) toxicity in C9ORF72-related ALS/FTD" (Gonzalez), "Lariat versus linear pre-mRNA splicing in S. pombe" (Chen)

    Hosted By: UMMS RNA Club; Sponsored by QIAGEN
    Location: 3rd Floor Seminar Room, Biotech II, UMMS
    9:00 am - 11:00 am

More Events


MassBiologics developing promising alternative treatment for diphtheria in wake of global antitoxin shortage

MassBiologics developing promising alternative treatment for diphtheria in wake of global antitoxin shortage

A worsening shortage of the antitoxin used to treat diphtheria, the deaths of two unvaccinated children to the disease in Europe and declining vaccination rates demonstrate the need for a new approach, and MassBiologics of UMass Medical School is developing one, according to a Jan. 13 story in the journal Science.

Read more
▴ Back To Top
Section Menu To Top